Seaport Therapeutics | Biotech/Pharma | Standout | Standout

Seaport Therapeutics

61 employees

Biotech/Pharma

Series B · $325.0M

Open positions (6)

Executive Director/Vice President, Clinical Development

Boston, MA

Executive Director, Program Leader

Boston, MA

StandoutYBacked by Y Combinator · P26

“LeBron has an agent. Why don’t you?”

— Now you have one too.

Talk to Standout

ProductHow it works For talent For companies Browse jobs Browse companies

CompanyAbout Blog Careers

ConnectTwitter / X LinkedIn

Standout.

Privacy Terms

Company details

Team Size61

IndustryBiotech/Pharma

Funding

Total raised

$325.0M

Last stage

Series B

Investors

ARCH Venture Partners

Sofinnova Investments

Third Rock Ventures

General Atlantic

PureTech Health

Founders

Daphne Zohar

Founder, CEO and Board Member of Seaport Therapeutics. Previously Founder and CEO of PureTech Health, where she also co-founded Karuna Therapeutics, which developed Cobenfy (KarXT) — acquired by Bristol Myers Squibb for $14 billion.

Steven M. Paul

Founder and Board Chair at Seaport Therapeutics. Former CEO and Chair of Karuna Therapeutics and former President of Research and Development at Eli Lilly. Over 40 years of experience as a physician-scientist in neuroscience and CNS drug discovery.

Michael Chen

Co-founder and CSO of Seaport Therapeutics. Previously Head of Innovation at PureTech Health, where he oversaw the neuropsychiatric medicines that led to Seaport's launch. Also Co-founder and Head of Research and Strategy at Sonde Health.

What happens next.

No applications, no recruiter spam. Just the intro.

Confirm the fit

A few questions to make sure this role is the right shape for you. Two minutes.

I pitch you to the company

I write the intro, send it to the founder, and handle the back-and-forth.

A meeting lands on your calendar

If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.